215 related articles for article (PubMed ID: 22252407)
1. Altered human CYP3A4 activity caused by Antley-Bixler syndrome-related variants of NADPH-cytochrome P450 oxidoreductase measured in a robust in vitro system.
Moutinho D; Marohnic CC; Panda SP; Rueff J; Masters BS; Kranendonk M
Drug Metab Dispos; 2012 Apr; 40(4):754-60. PubMed ID: 22252407
[TBL] [Abstract][Full Text] [Related]
2. Reduction in hepatic drug metabolizing CYP3A4 activities caused by P450 oxidoreductase mutations identified in patients with disordered steroid metabolism.
Flück CE; Mullis PE; Pandey AV
Biochem Biophys Res Commun; 2010 Oct; 401(1):149-53. PubMed ID: 20849814
[TBL] [Abstract][Full Text] [Related]
3. Diminished FAD binding in the Y459H and V492E Antley-Bixler syndrome mutants of human cytochrome P450 reductase.
Marohnic CC; Panda SP; Martásek P; Masters BS
J Biol Chem; 2006 Nov; 281(47):35975-82. PubMed ID: 16998238
[TBL] [Abstract][Full Text] [Related]
4. Mutations of human cytochrome P450 reductase differentially modulate heme oxygenase-1 activity and oligomerization.
Marohnic CC; Huber Iii WJ; Patrick Connick J; Reed JR; McCammon K; Panda SP; Martásek P; Backes WL; Masters BS
Arch Biochem Biophys; 2011 Sep; 513(1):42-50. PubMed ID: 21741353
[TBL] [Abstract][Full Text] [Related]
5. Substrate-specific modulation of CYP3A4 activity by genetic variants of cytochrome P450 oxidoreductase.
Agrawal V; Choi JH; Giacomini KM; Miller WL
Pharmacogenet Genomics; 2010 Oct; 20(10):611-8. PubMed ID: 20697309
[TBL] [Abstract][Full Text] [Related]
6. Impairment of human CYP1A2-mediated xenobiotic metabolism by Antley-Bixler syndrome variants of cytochrome P450 oxidoreductase.
Kranendonk M; Marohnic CC; Panda SP; Duarte MP; Oliveira JS; Masters BS; Rueff J
Arch Biochem Biophys; 2008 Jul; 475(2):93-9. PubMed ID: 18455494
[TBL] [Abstract][Full Text] [Related]
7. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase.
Flück CE; Nicolo C; Pandey AV
Fundam Clin Pharmacol; 2007 Aug; 21(4):399-410. PubMed ID: 17635179
[TBL] [Abstract][Full Text] [Related]
8. Instability of the Human Cytochrome P450 Reductase A287P Variant Is the Major Contributor to Its Antley-Bixler Syndrome-like Phenotype.
McCammon KM; Panda SP; Xia C; Kim JJ; Moutinho D; Kranendonk M; Auchus RJ; Lafer EM; Ghosh D; Martasek P; Kar R; Masters BS; Roman LJ
J Biol Chem; 2016 Sep; 291(39):20487-502. PubMed ID: 27496950
[TBL] [Abstract][Full Text] [Related]
9. Effects of genetic variants of human P450 oxidoreductase on catalysis by CYP2D6 in vitro.
Sandee D; Morrissey K; Agrawal V; Tam HK; Kramer MA; Tracy TS; Giacomini KM; Miller WL
Pharmacogenet Genomics; 2010 Nov; 20(11):677-86. PubMed ID: 20940534
[TBL] [Abstract][Full Text] [Related]
10. CYP3A4 expressed by insect cells infected with a recombinant baculovirus containing both CYP3A4 and human NADPH-cytochrome P450 reductase is catalytically similar to human liver microsomal CYP3A4.
Lee CA; Kadwell SH; Kost TA; Serabjit-Singh CJ
Arch Biochem Biophys; 1995 May; 319(1):157-67. PubMed ID: 7771780
[TBL] [Abstract][Full Text] [Related]
11. Influence of various polymorphic variants of cytochrome P450 oxidoreductase (POR) on drug metabolic activity of CYP3A4 and CYP2B6.
Chen X; Pan LQ; Naranmandura H; Zeng S; Chen SQ
PLoS One; 2012; 7(6):e38495. PubMed ID: 22719896
[TBL] [Abstract][Full Text] [Related]
12. [Antley-Bixler syndrome or POR deficiency?].
Tomková M; Marohnic CC; Baxová A; Martásek P
Cas Lek Cesk; 2008; 147(5):261-5. PubMed ID: 18630181
[TBL] [Abstract][Full Text] [Related]
13. Human cytochrome P450 oxidoreductase deficiency caused by the Y181D mutation: molecular consequences and rescue of defect.
Marohnic CC; Panda SP; McCammon K; Rueff J; Masters BS; Kranendonk M
Drug Metab Dispos; 2010 Feb; 38(2):332-40. PubMed ID: 19884324
[TBL] [Abstract][Full Text] [Related]
14. Consequences of POR mutations and polymorphisms.
Miller WL; Agrawal V; Sandee D; Tee MK; Huang N; Choi JH; Morrissey K; Giacomini KM
Mol Cell Endocrinol; 2011 Apr; 336(1-2):174-9. PubMed ID: 21070833
[TBL] [Abstract][Full Text] [Related]
15. In Silico Analysis of PORD Mutations on the 3D Structure of P450 Oxidoreductase.
Nurhafizuddin M; Azizi A; Ming LC; Shafqat N
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889519
[TBL] [Abstract][Full Text] [Related]
16. P450 Oxidoreductase deficiency: Analysis of mutations and polymorphisms.
Burkhard FZ; Parween S; Udhane SS; Flück CE; Pandey AV
J Steroid Biochem Mol Biol; 2017 Jan; 165(Pt A):38-50. PubMed ID: 27068427
[TBL] [Abstract][Full Text] [Related]
17. P450 oxidoreductase deficiency: a disorder of steroidogenesis with multiple clinical manifestations.
Miller WL
Sci Signal; 2012 Oct; 5(247):pt11. PubMed ID: 23092891
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for human NADPH-cytochrome P450 oxidoreductase deficiency.
Xia C; Panda SP; Marohnic CC; Martásek P; Masters BS; Kim JJ
Proc Natl Acad Sci U S A; 2011 Aug; 108(33):13486-91. PubMed ID: 21808038
[TBL] [Abstract][Full Text] [Related]
19. Diversity and function of mutations in p450 oxidoreductase in patients with Antley-Bixler syndrome and disordered steroidogenesis.
Huang N; Pandey AV; Agrawal V; Reardon W; Lapunzina PD; Mowat D; Jabs EW; Van Vliet G; Sack J; Flück CE; Miller WL
Am J Hum Genet; 2005 May; 76(5):729-49. PubMed ID: 15793702
[TBL] [Abstract][Full Text] [Related]
20. Kinetics of testosterone 6beta-hydroxylation in the reconstituted system with similar ratios of purified CYP3A4, NADPH-cytochrome p450 oxidoreductase and cytochrome B5 to human liver microsomes.
Taguchi M; Imaoka S; Yoshii K; Kobayashi K; Hosokawa M; Shimada N; Funae Y; Chiba K
Res Commun Mol Pathol Pharmacol; 2001 Jul; 109(1-2):53-63. PubMed ID: 11458985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
